Avammune Therapeutics
Bangalore, India· Est.
Platform biotech creating small‑molecule and radioligand cancer immunotherapies for solid tumors.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Platform biotech creating small‑molecule and radioligand cancer immunotherapies for solid tumors.
OncologyImmunology
Technology Platform
An integrated discovery engine combining bioinformatics, innate immunology, medicinal chemistry, and high‑throughput biology to design small‑molecule modulators of intracellular immune pathways and radioligand therapeutics.
Opportunities
Leverage a unique small‑molecule immunomodulation platform to fill gaps in checkpoint‑resistant solid tumor therapy and form strategic partnerships for IND development.
Risk Factors
Early‑stage pre‑clinical status, dependence on external financing, and competition from larger immuno‑oncology players could delay asset progression.
Competitive Landscape
Competes with biotech firms developing small‑molecule immune modulators and radioligand therapies, but differentiates through its focus on intracellular DNA/RNA‑binding targets and a modality‑agnostic discovery engine.